Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Short term Debt (2020 - 2025)

Puma Biotechnology (PBYI) has disclosed Short term Debt for 5 consecutive years, with $22.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Short term Debt fell 50.31% year-over-year to $22.5 million, compared with a TTM value of $22.5 million through Dec 2025, down 50.31%, and an annual FY2025 reading of $22.5 million, down 50.31% over the prior year.
  • Short term Debt was $22.5 million for Q4 2025 at Puma Biotechnology, down from $33.7 million in the prior quarter.
  • Across five years, Short term Debt topped out at $45.3 million in Q1 2024 and bottomed at $11.3 million in Q2 2023.
  • Average Short term Debt over 4 years is $33.8 million, with a median of $34.0 million recorded in 2023.
  • The sharpest move saw Short term Debt surged 300.01% in 2024, then tumbled 50.31% in 2025.
  • Year by year, Short term Debt stood at $31.4 million in 2021, then rose by 8.17% to $34.0 million in 2023, then skyrocketed by 33.33% to $45.3 million in 2024, then crashed by 50.31% to $22.5 million in 2025.
  • Business Quant data shows Short term Debt for PBYI at $22.5 million in Q4 2025, $33.7 million in Q3 2025, and $34.0 million in Q2 2025.